Clinical Research Papers:
Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma
Metrics: PDF 589 views | HTML 970 views | ?
Rosamaria Tedeschi1,*, Ettore Bidoli2,*, Maria Teresa Bortolin1, Ornella Schioppa3, Emanuela Vaccher3, Paolo De Paoli4
1Microbiology-Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
2Epidemiology and Biostatistic Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
3Medical Oncology A, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
4Scientific Directorate, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
*These authors have contributed equally to this work
Rosamaria Tedeschi, e-mail: firstname.lastname@example.org
Keywords: Kaposi sarcoma (KS), combination antiretroviral therapy (cART), G-CSF, HGF, endoglin
Received: April 17, 2015 Accepted: June 26, 2015 Published: July 09, 2015
This study aimed to evaluate plasma concentration of selected cancer-associated inflammatory and immune-modulated cytokines in HIV+ patients with advanced Kaposi sarcoma (KS), and to explore candidate biomarkers capable of predicting clinical outcome in response to chemotherapy (CT) plus combination antiretroviral therapy (cART).
Thirty-seven plasma cytokines/chemokines were assessed by Luminex technology in 27 consecutive HIV+ KS patients, followed-up during CT and cART of maintanence (m-cART). Associations between plasma concentration of biomarkers and patient clinical response to m-cART were evaluated by means of Hazard Ratios (HRs) and corresponding 95% Confidence Intervals (CIs).
Plasma baseline concentration of Granulocyte colony-stimulating factor (G-CSF), Hepatocyte growth factor (HGF) and endoglin were found to be associated with m-cART clinical response (HR:1.56, 95%CI:1.09–2.22, p = 0.01; HR:0.32, 95% CI:0.10–0.99, p = 0.05; HR:0.72, 95% CI:0.54–0.96, p = 0.03, respectively). The multivariate analysis confirmed the associations of baseline plasma G-CSF and HGF concentration with m-cART clinical complete remission response (HR:1.78, 95% CI:1.15–2.74, p = 0.009; HR:0.19, 95% CI:0.04–0.95, p = 0.04).
Our exploratory study suggested that plasma G-CSF, HGF and endoglin may be novel predictors of clinical response during m-cART in HIV+ KS patients. Nonetheless, these findings should be further validated in an independent population study.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.